J Natl Cancer Inst: A tumor infiltrating lymphocyte imaging marker for risk stratification of HPV-related oropharyngeal cancer!

Compared with non-viral-related oropharyngeal squamous cell carcinoma (OPCSCC), HPV-related oropharyngeal squamous cell carcinoma has an excellent control rate
.

A number of trials are actively testing whether reducing the intensity of treatment for these patients can reduce treatment-related toxicity while maintaining tumor balance

Researchers such as Corredor have developed a biomarker OP-TIL that can characterize the spatial interaction between tumor infiltrating lymphocytes (TIL) and surrounding cells in histological images
.

This study explored whether OP-TIL can further divide phase I HPV-related OPSCC patients into low-risk groups and high-risk groups, and help patients choose to downgrade clinical trials

H&E slides of 439 patients with stage I HPV-related OPSCC from 6 institutional cohorts were used to analyze the correlation between IP-TIL and patient prognosis
.

Then another cohort study (n=94) was used to clarify the most prognostic features, and the Cox retrospective model was trained to predict the risk of recurrence and death

DFS in low-risk group and high-risk group with a history of smoking ≤10 packs/year

DFS in low-risk group and high-risk group with a history of smoking ≤10 packs/year

OP-TIL divided stage I HPV-related OPSCC patients with a history of smoking ≤30 packs/year into a low-risk group (2-year disease-free survival rate [DFS] 94.
2%; 5-year DFS 88.
4%) and a high-risk group (2 Annual DFS 82.
5%; 5-year DFS 74.
2%; Hazard ratio 2.
56, p<0.
001) ; In the multivariate analysis of DFS, even after adjusting for age, smoking status, T and N classification, and treatment plan, the above correlation It still exists (hazard ratio 2.
27, p=0.
003)
.

OP-TIL divided stage I HPV-related OPSCC patients with a history of smoking ≤30 packs/year into a low-risk group (2-year disease-free survival rate [DFS] 94.
2%; 5-year DFS 88.
4%) and a high-risk group (2 Annual DFS 82.
5%; 5-year DFS 74.
2%; risk ratio 2.
56, p<0.
001) OP-TIL divided patients with stage I HPV-related OPSCC with a history of smoking ≤30 packs/year into a low-risk group (2 years disease-free survival Rate [DFS] 94.
2%; 5-year DFS 88.
4%) and high-risk group (2-year DFS 82.
5%; 5-year DFS 74.
2%; risk ratio 2.
56, p<0.
001)

DFS in low-risk group and high-risk group with a history of smoking ≤30 packs/year

DFS in low-risk group and high-risk group with a history of smoking ≤30 packs/year

In summary, OP-TIL can screen out low-risk stage I HPV-related OPSCC patients who may be degraded
.

OP-TIL is expected to become a biomarker for clinical optimization of patient downgrade selection

OP-TIL can screen low-risk stage I HPV-related OPSCC patients who can be screened or degraded treatment OP-TIL can screen low-risk stage I HPV-related OPSCC patients who can be downgraded treatment

 

Original source:

Original source:

Corredor Germán,Toro Paula,Koyuncu Can et al.

Leave a message here